Research programme: recombinant coagulation factors - CSL Behring

Drug Profile

Research programme: recombinant coagulation factors - CSL Behring

Alternative Names: CSL 650; rvWF-FP

Latest Information Update: 03 Apr 2012

Price : $50

At a glance

  • Originator CSL Behring
  • Class Blood coagulation factors; Recombinant fusion proteins
  • Mechanism of Action Factor VIIa stimulants; Von Willebrand factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Haemophilia

Most Recent Events

  • 03 Apr 2012 rvWF-FP is still in preclinical development for haemophilia in the US
  • 08 Dec 2011 CSL initiates research programme for rvWF-FP in Haemophilia
  • 16 Apr 2010 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top